MabGenesis announced its results after the close on 12 November. Ordinary income for the cumulative second quarter of the fiscal year ending March 2027 (April–September) was a ¥77 million loss on a non-consolidated basis.
MabGenesis announced its results after the close on 12 November and reported ordinary income for the cumulative second quarter (April–September) of the fiscal year ending March 2028.
Ordinary income was a ¥77 million loss on a non-consolidated basis, while the corresponding figure for the same period a year earlier was not disclosed.
The article concludes by prompting readers to check the earnings summary, and states that it was prepared using numerical data published by the company as an information source for investment decisions.